IQV vs. ICLR, CRL, INCY, MEDP, TAK, IDXX, COR, HUM, CNC, and ALC
Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Charles River Laboratories International (CRL), Incyte (INCY), Medpace (MEDP), Takeda Pharmaceutical (TAK), IDEXX Laboratories (IDXX), Cencora (COR), Humana (HUM), Centene (CNC), and Alcon (ALC). These companies are all part of the "medical" sector.
IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.
IQVIA has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
IQVIA received 43 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.03% of users gave IQVIA an outperform vote while only 64.80% of users gave ICON Public an outperform vote.
IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
In the previous week, IQVIA had 4 more articles in the media than ICON Public. MarketBeat recorded 6 mentions for IQVIA and 2 mentions for ICON Public. ICON Public's average media sentiment score of 0.96 beat IQVIA's score of 0.61 indicating that ICON Public is being referred to more favorably in the news media.
IQVIA presently has a consensus target price of $256.80, suggesting a potential upside of 1.67%. ICON Public has a consensus target price of $312.64, suggesting a potential downside of 5.12%. Given IQVIA's higher probable upside, research analysts plainly believe IQVIA is more favorable than ICON Public.
89.6% of IQVIA shares are held by institutional investors. Comparatively, 95.6% of ICON Public shares are held by institutional investors. 1.6% of IQVIA shares are held by insiders. Comparatively, 44.0% of ICON Public shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
IQVIA has a net margin of 9.06% compared to ICON Public's net margin of 7.54%. IQVIA's return on equity of 29.32% beat ICON Public's return on equity.
Summary
IQVIA beats ICON Public on 11 of the 18 factors compared between the two stocks.
Get IQVIA News Delivered to You Automatically
Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools